Search Results

Gelesis Holdings, Inc. today reported financial results for the year ended December 31, 2022.

A new paper published today in Cell Reports Medicine suggests that weight loss resulting from Gelesis’ superabsorbent hydrogel treatment is not only a result of its space-occupying properties; the mechanical composition and structure of the material may have notable benefits for gut and metabolic health.

Gelesis Holdings today reported financial results for the third quarter of 2022.

Gelesis (NYSE: GLS), the maker of Plenity for weight management, today announced that the Company will participate in the 25th Annual ICR Conference in Orlando, Florida on Monday, January 9, 2023.

Gelesis (NYSE: GLS), the maker of Plenity for weight management, today reported financial results for the second quarter of 2022.

Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”) the maker of Plenity for weight management, today released new data at Obesity Week in San Diego.

Gelesis Holdings, Inc. (NYSE:GLS) (“Gelesis” or the “Company”), the maker of Plenity® for weight management, today announced that the Company will report financial results for the Second Quarter ended June 30, 2022, on August 15, 2022 prior to the market open.

Gelesis, the maker of Plenity for weight management, reported financial results for the first quarter of 2022.

Gelesis Holdings Inc. today announced that the Company is participating in a fireside chat with IPO Edge today at 2:00 PM ET.

Gelesis Holdings Inc. noted that the Company received a notification letter from the New York Stock Exchange advising that because the average closing price of the Company’s common stock was less than $1.00 over a consecutive 30 trading-day period, it is not in compliance with Section 802.01C of the NYSE Listed Company Manual.